Erika L. Hellenbart
Clinical Assistant Professor, College of Pharmacy - Pharmacy Practice
Contact
Office Phone:
Email:
Related Sites:
About Heading link
Teaching and Supervision Heading link
PDAT 5: Cardiovascular (PHAR 505), 1/9/2023 – 4/28/2023
PDAT 5: Cardiovascular (PHAR 505), 1/9/2023 – 4/28/2023
Adv Topics in Ambulatory Care (PMPR 348), 1/9/2023 – 4/28/2023
Adv Topics in Ambulatory Care (PMPR 348), 1/9/2023 – 4/28/2023
PDAT 5: Cardiovascular (PHAR 505), 1/10/2022 – 4/29/2022
PDAT 5: Cardiovascular (PHAR 505), 1/10/2022 – 4/29/2022
Adv Topics in Ambulatory Care (PMPR 348), 1/10/2022 – 4/29/2022
Adv Topics in Ambulatory Care (PMPR 348), 1/10/2022 – 4/29/2022
Adv Topics in Ambulatory Care (PMPR 348), 1/10/2022 – 4/29/2022
Selected Grants
PRogram to Educate & VaccinatE uNderserved members of The public (PREVENT) Pilot, Mobile Care Fdn., 11/1/2022 - 5/31/2023, Obligated Amount: $17325; Anticipated Amount: $17325
COVID-19 Outpatient thrombosis prevention trial (ACTIV 4B), National Institutes of Health and National Heart, Lung, and Blood Institute., 12/1/2020 - 8/12/2021, No Obligated Amount Set; No Anticipated Amount Set
COVID-19 Outpatient thrombosis prevention trial (ACTIV 4B), National Institutes of Health and National Heart, Lung, and Blood Institute., 12/1/2020 - 8/12/2021, No Obligated Amount Set; No Anticipated Amount Set
Impact of socio-environmental factors on optimal anticoagulation outcomes in underserved patients, University of Illinois at Chicago, College of Pharmacy: Riback Grant., 2018 - 2019, No Obligated Amount Set; No Anticipated Amount Set
Global registry on long-term oral anti-thrombotic treatment in patients with atrial fibrillation, Boehringer Ingelheim., 2016 - 2019, No Obligated Amount Set; No Anticipated Amount Set
Patient-centered anticoagulation self-monitoring in minority patients, National Institutes of Health., 2016 - 2017, No Obligated Amount Set; No Anticipated Amount Set
Impact of novel oral anticoagulants on quality of life in an inner-city underserved population, American Pharmacists Association: APhA Incentive Grants for Practitioner Innovation in Pharmaceutical Care 2012., 2012 - 2013, Obligated Amount: $1000; Anticipated Amount: $1000
Selected Publications
Shapiro, Nancy, Hellenbart, erika. (2023). Koda-Kimble and Young’s Applied Therapeutics: The Clinical Use of Drugs, Twelfth edition textbook. Wolters Kluwer Health, Inc.. Koda-Kimble and Young’s Applied Therapeutics: The Clinical Use of Drugs, Twelfth edition. Wolters Kluwer Health, Inc.
Elmes, AT, Hellenbart, EL. (2022). Vericiguat (Verquvo) for the Treatment of Heart Failure. American Family Physician, 106, (5), 582-583.
★ Whittemore, H, Posen, AK, Hellenbart, EL, Groo, V, Wenzler, E, Tilton, JJ. (2021). The Impact of Body Weight and Renal Function on the Risk of Bleeding With Direct Oral Anticoagulants in Atrial Fibrillation. Annals of Pharmacotherapy, 55, (11), 1309-1317. doi:10.1177/1060028021995201.
Shapiro, Nancy, Hellenbart, Erika. (2021). Applied Therapeutics: The Clinical Use of Drugs. Applied Therapeutics: The Clinical Use of Drugs. Wolters Kluwer Health, Inc.
Hellenbart, EL, Griffin, T, DiDomenico, RJ. (2020). Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults. Pharmacotherapy, 40, (6), 544-564. doi:10.1002/phar.2391.
Hellenbart, EL, Faulkenberg, KD, Finks, SW. (2017). Evaluation of bleeding in patients receiving direct oral anticoagulants. Vascular Health and Risk Management, 13, 325-342. doi:10.2147/VHRM.S121661.
Hellenbart, EL. (2017). Venous thromboembolism and pregnancy. Oral Anticoagulation Therapy: Cases and Clinical Correlation. (pp. 259-267). doi:10.1007/978-3-319-54643-8_37.
Hellenbart, E, Drambarean, B, Lee, J, Nutescu, EA. (2015). The evolving role of dabigatran etexilate in clinical practice. Expert Opinion on Pharmacotherapy, 16, (13), 2053-2072. doi:10.1517/14656566.2015.1074179.
Nutescu, E, Chuatrisorn, I, Hellenbart, E. (2011). Drug and dietary interactions of warfarin and novel oral anticoagulants: An update. Journal of Thrombosis and Thrombolysis, 31, (3), 326-343. doi:10.1007/s11239-011-0561-1.
Professional Leadership
Cardiology PRN Nominations Committee, 12/1/2021 - Present
Education
Degrees:
Doctor of Pharmacy (Cum Laude), Ohio State University, United States, 2009
Bachelor of Science, University of Windsor, Canada, 2005
Postgraduate Training:
ASHP-Accredited PGY-1 Pharmacy Residency, Midwestern University Chicago College of Pharmacy, United States, 2010
Licensures and Certifications
Board Certified Pharmacotherapy Specialist, Board of Pharmacy Specialties, 1/1/2010 - Present
Registered Pharmacist, State of Illinois, 1/1/2009 - Present
APhA Pharmacy-Based Immunization Delivery, American Pharmacists Association, 1/1/2007 - Present
Heartsaver® AED Program, American Heart Association, 1/1/2007 - Present
Residents Teaching and Learning Curriculum, Midwestern University, 2009 - 2010
Illinois Poison Prevention Education Training, State of Illinois, 2009 - 2010
Selected Presentations
Hellenbart, Erika. (2022 April 23). Diabetes and Heart Disease. 5th Annual Symposium on Heart to Heart: Cardiology updates for the primary care and hospital medicine provider. Chicago, IL.
Hellenbart, Erika. (2021 September 13). Turning Lemons into Lemonade: Practical Approaches to Address the Financial Toxicity of Heart Failure Therapies. Heart Failure Society of America 2021 Scientific Meeting. Denver, CO.